Nuwellis, Inc. Q3 2026 Earnings Call Summary Moby Intelligence Thu, November 12, 2026 at 1:19 PM EST 2 min read NVDA -4.52% NUWE -2.89% Trade NVIDIA on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Gross margin expanded 430 basis points to 70% in the quarter, driven by higher average selling prices, favorable product mix, and the continued benefits of the transition to a contract manufacturing model.
Operating loss improved by 24% year-over-year as management reduced operating expenses by 13% through disciplined spending and alignment of resources toward high-priority growth initiatives.
Pediatric sales grew 20% in the quarter and 26% year-to-date, serving as the company's primary growth driver and supported by the publication of the ULTRA-Peds Registry in a peer-reviewed journal.
The company is broadening its cardiorenal platform through capital-efficient co-promotion and distribution agreements for AtriAmp and Zorro-Flow, leveraging the existing sales force and customer relationships.
Year-to-date console sales increased 88% compared to the prior year, which management views as a critical indicator for expanding future recurring circuit revenue.
Management attributed the flat year-over-year revenue comparison to a one-time $400,000 backorder fulfillment in the prior year quarter, noting that underlying performance grew by 20% when excluding that benefit.
A 510(k) application was submitted to the FDA to expand the Aquadex SmartFlow system indication to include patients weighing as low as 5 kilograms, significantly broadening the addressable pediatric population.
Management expects a sequence of product launches in early 2027, including the Aquadex SmartView user interface and the Zorro-Flow external urine collection system in Q1, followed by Pressure IQ in the first half of the year.
Current cash and cash equivalents of $8.3 million are expected to provide a financial runway through the second quarter of 2027.
The company is evaluating opportunities to incorporate Clarity Prime's automated kidney function monitoring technology into other products and clinical applications beyond its original scope.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
The reported net loss of $2 million compared to a prior year net income was primarily due to a significant non-cash gain from warrant liability fair value changes in the 2025 period.
During the third quarter, the company strengthened its balance sheet by raising approximately $8.1 million in total proceeds through a registered direct offering, warrant exercises, and an at-the-market program.
